Credevo

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Credevo, Health/Medical/ Pharmaceuticals, Singapore.

A global Clinical Trial Organization (CTO) providing comprehensive clinical trial services for pharmaceuticals, biologics, medical devices and healthcare products Credevo provides strategic support for healthcare products including;

- Drugs

- Biologics

- Health Supplements (Nutraceuticals)

- IVD and medical devices

- Cosmetics

In areas of

- Regulatory

- Clinical Development

- Business Development Support

- Licensing (out-/in-)

- Feasibility

05/06/2026

A sponsor building APAC clinical capability for the first time usually comes in with SOPs designed for somewhere else.

The US and EU frameworks are in the documentation. What's missing is the APAC layer. Country-specific regulatory requirements, local IRB processes, monitoring expectations in Thailand, India, or Malaysia. A CRO that applies the sponsor's global SOPs without flagging the gaps creates compliance risk without naming it.

What works is a review before the first site opens. Which parts apply to the APAC context directly? Where does a country-specific supplement need to be written? Where is the CRO operating under its own SOPs with documented sponsor agreement? What triggers a review when something changes?

This doesn't need to add weeks to startup. It needs to happen before ex*****on begins.

What a QMS framework looks like in APAC practice, including what global SOPs typically miss: https://credevo.com/articles/2025/03/15/quality-by-design-in-clinical-trials-building-maintaining-a-qms-framework/

If the SOP integration hasn't been fully worked through for your first APAC study, we're here: https://credevo.com/contact

04/06/2026

RWE studies and interventional trials run differently from day one. That difference needs to be designed in, not added after.

An observational study doesn't randomise patients. It captures what happens in routine clinical practice. Sites report what they do. Data comes from EHRs, registries, claims, patient-reported outcomes. The statistical approach handles confounding differently from a randomised design. The evidentiary standard and regulatory acceptance are different.

This matters at the design stage. A Phase IV post-marketing study required by a regulator has its own protocol structure. A PMCF study for a medical device under EU MDR has specific requirements. An RWE study supporting label expansion needs a design the relevant authority will accept.

Credevo runs RWE studies across APAC and the United States, including Phase IV studies, registry studies, PASS, and PMCF studies for medical devices.

We've written about how real-world data trial designs work in practice: https://credevo.com/articles/2022/04/15/trial-designs-using-real-world-data-rwd/

If you're planning an RWE study and want to think through the design requirements, we're here: https://credevo.com/contact

03/06/2026

The protocol looked right on paper. The problems appeared four weeks after the first patient was enrolled.

An eligibility criterion that excluded more patients than expected. A stratification structure site coordinators couldn't apply consistently. A comparator arm the investigators flagged at the SIV as no longer reflecting local standard of care.

These aren't errors. They're what happens when a protocol is finalized without input from the people who will run it.

The way to catch them is to engage investigators before lock. Not at SIV. Before. They'll surface what looks clean on paper but doesn't hold on the ground.

Credevo runs early investigator engagement as part of the full-service model and as a standalone service across all 13 operating markets.

We've covered what early site engagement surfaces before protocol lock, including how it affects comparator arm and eligibility design: https://credevo.com/articles/2025/05/15/why-early-site-engagement-matters-insights-into-soc-comparator-arms-and-site-interest/

If your protocol is at a stage where investigator input would still be useful, we're here: https://credevo.com/contact

02/06/2026

Most guidance on APAC clinical trials is written for sponsors who already know the region.

For a small biotech doing their first APAC study, the more useful starting point is knowing which decisions are being made on information that won't hold once ex*****on starts.

Published regulatory timelines are not planning timelines. Country-level epidemiology doesn't predict site-level patient availability. Investigator relationships built before the study starts change how the study runs.

The gap between what's written down and what actually happens tends to be wider in APAC than in markets where sponsors have more accumulated experience.

We've written about what APAC clinical operations actually require to go well: https://credevo.com/articles/2023/08/25/choosing-asia-pacific-for-your-clinical-trials-strategic-insights/

If you're planning your first APAC study, we're here: https://credevo.com/contact

01/06/2026

A sponsor had their country list set before feasibility started. Three weeks in, two of the four markets changed.

The assumptions hadn't been tested. Site landscapes had shifted. Investigators had moved. Competing trials had filled the relevant recruitment windows. One country's regulatory timeline for this study type had changed, not because the rules changed, but because review volumes had.

Two replacement markets worked better. The study started within two weeks of the original plan.

Feasibility isn't a box to tick. It's the work that makes everything else reliable.

We've covered what rigorous APAC feasibility looks like in practice, beyond the standard questionnaire: https://credevo.com/articles/2025/07/25/beyond-the-feasibility-questionnaire-rethinking-feasibility-assessments-in-asia-pacific-trials/

If you're selecting countries for your study, we're here: https://credevo.com/contact

29/05/2026

A sponsor's Phase III protocol had a comparator arm built from published guidelines. The investigators in the target markets said they hadn't used it as a first-line treatment in that population in some time.

Standard of care on the ground is not always what the guidelines say. Clinical practice adapts. Local investigators know their patients in a way a desk review can't replicate.

Found six weeks before lock. Protocol revised. Ethics submission went in with the correct design. The study started on time.

If this had surfaced after site activation: a protocol amendment, re-submission, months of delay. The cost of catching it before the lock is a revision. The cost of catching it after is an amendment.

We've written about what structured investigator engagement is before lock catches, including SOC and comparator arm assumptions: https://credevo.com/articles/2025/05/15/why-early-site-engagement-matters-insights-into-soc-comparator-arms-and-site-interest/

If your protocol is at a stage where investigator input could still change something, we're here: https://credevo.com/contact

28/05/2026

Sponsors who have run good APAC trials talk about the work that happened before the first submission. Investigator engagement before protocol lock. Regulatory timelines were built from what the country was actually running at. Site selection based on direct conversations, not just accreditation lists.

The feasibility was specific to the study. The protocol had real input from investigators in the target markets. There was one accountable contact for the sponsor.

None of this is unusual to describe. The gap between what proposals say and what ex*****on delivers is where most problems live. Sponsors who know this ask different questions in the selection process.

What clinical operations in APAC actually require: https://credevo.com/articles/2025/08/15/mastering-clinical-operations-in-asia-pacific-overcoming-challenges-with-smart-solutions/

If you're in the planning phase of an APAC study, we're happy to share what we see working: https://credevo.com/contact

27/05/2026

Sri Lanka's clinical research market is active, underused, and runs on relationships.

Patient populations are available. NMRA submissions are manageable for sponsors who know the process. But practical knowledge of how things move, which investigators have real capacity, and how sites actually operate, is less widely distributed than in India or Thailand.

Under the FSP model, Credevo provides CRAs, study coordinators, and clinical trial managers who work in Sri Lanka, know the NMRA process, and have current relationships with the sites and investigators your study depends on. Your systems and SOPs. Credevo's people.

FSP is available across Sri Lanka, Singapore, Thailand, Malaysia, and India.

We've covered how the FSP model is structured in practice: https://credevo.com/articles/2025/02/25/smarter-clinical-trial-management-in-india-why-the-fsp-functional-service-provider-fsp-model-makes-sense/

If you're working out how to staff a Sri Lanka study, we're here: https://credevo.com/contact

26/05/2026

The concern isn't whether the CRO has good SOPs. It's whether your own processes hold once another organization's SOPs are in the room.

Standard CRO processes are designed to be generally applicable, not for a specific sponsor's quality system or manufacturing context. When the sponsor has specific requirements, that assumption fails.

What works is a documented review before the study starts, where the CRO adopts the sponsor's SOPs, where adaptation is needed, and where the two systems need bridging. Once the study is running, SOP gaps become protocol deviations.

How QMS frameworks accommodate sponsor-specific requirements: https://credevo.com/articles/2025/03/15/quality-by-design-in-clinical-trials-building-maintaining-a-qms-framework/

If the SOP question hasn't been properly addressed in a proposal you're reviewing, we'd be glad to look at it: https://credevo.com/contact

25/05/2026

Medical monitoring is the FSP function that gets missed most often.

CRAs and data managers are visible. Medical monitors are less visible and more consequential. They're the clinical judgment layer between what a site reports and what the sponsor receives. Protocol deviations, AE narratives, safety signals, and eligibility issues.

Under the FSP model, the medical monitor Credevo works within your pharmacovigilance system, your SOPs, and your escalation paths. Available across Singapore, Thailand, Malaysia, India, and Sri Lanka.

How clinical monitoring and oversight work in APAC trials: https://credevo.com/articles/2024/06/25/clinical-trial-monitoring-key-strategies/

If medical oversight is the gap in your APAC study staffing, we're here: https://credevo.com/contact

Address

Singapore

Website

https://credevo.com/

Alerts

Be the first to know and let us send you an email when Credevo posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Health & Beauty Business in Singapore?